We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
What is the risk of intensifying platelet inhibition beyond clopidogrel? A systematic review and a critical appraisal of the role of prasugrel.
- Authors
Testa, L.; Bhindi, R.; Van Gaal, W. J.; Latini, R. A.; Pizzocri, S.; Lanotte, S.; Zoccai, G. G. L. Biondi; Valgimigli, M.; Laudisa, M. L.; Brambilla, N.; Banning, A. P.; Bedogni, F.
- Abstract
Thienopyridines are a class of drug targeting the platelet adenosine diphosphate 2 receptor. They have been shown to significantly reduce platelet activity exerting an important role in those clinical settings in which such an effect is beneficial. Ticlopidine was first to be introduced several years ago but it was quickly replaced by clopidogrel as it had a better risk/benefit profile. Recently, prasugrel has been developed and tested in several ex vivo studies and clinical trials showing able to provide a more powerful antiplatelet effect at the expense of a higher risk of bleeding complications. Great debate rose around its recent approval in the US as well as in Europe. This review aims at exploring the development and available clinical data of this third-generation thienopyridine while discussing its practical implementation in routine practice.
- Subjects
DRUGS; BLOOD platelets; PYROPHOSPHATES; TICLOPIDINE; CLOPIDOGREL
- Publication
QJM: An International Journal of Medicine, 2010, Vol 103, Issue 6, p367
- ISSN
1460-2725
- Publication type
Article
- DOI
10.1093/qjmed/hcq017